OPRM1 rs2075572 has potential to affect plasma buprenorphine level in opioid users, but not OPRM1 rs562859
Yazarlar (4)
Prof. Dr. Dilek Akyüzlü Ankara Üniversitesi, Türkiye
Doç. Dr. Selin ÖZKAN KOTİLOĞLU Kırşehir Ahi Evran Üniversitesi, Türkiye
Mustafa Danışman Ankara Training & Res Hosp AMATEM Clin
Prof. Dr. Ceylan Bal Ankara Yıldırım Beyazıt Üniversitesi, Türkiye
| Makale Türü | Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | NEUROSCIENCE LETTERS (Q4) | ||
| Dergi ISSN | 0304-3940 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | Türkçe | Basım Tarihi | 06-2024 |
| Cilt / Sayı / Sayfa | 834 / 0 / 137846–0 | DOI | 10.1016/j.neulet.2024.137846 |
| Makale Linki | http://dx.doi.org/10.1016/j.neulet.2024.137846 | ||
| Özet |
| OPRM1 gene encoding mu-opioid receptor (MOR) is the primary candidate gene for buprenorphine (BUP) pharmacogenetics. OPRM1 undergoes alternative splicing leading to multiple MOR subtypes. Thus, in the current study 2 SNPs (rs1799972 and rs562859) were selected due to evidence for their contribution to alternative splicing of OPRM1.The effects of 2 SNPs of OPRM1 gene on plasma buprenorphine and norbuprenorphine levels in a sample of 233 OUD patients receiving BUP/naloxone were examined. Polymorphisms were analyzed by PCR and RFLP. BUP and norbuprenorphine concentrations in plasma were measured by LC–MS/MS.OPRM1 rs2075572 GC + CC (0.12 ng/ml) had significantly higher plasma BUP level compared to GG (0.084 ng/ml) (p = 0.043). Although there was not a statistically significant difference between OPRM1 rs562859 genotypes (p = 0.46), patients with OPRM1 rs562859 … |
| Anahtar Kelimeler |
| Pharmacodynamics | Buprenorphine | Alternative splicing | OPRM1 rs2075572 |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Web of Science | 2 |
| Google Scholar | 2 |